Abstract
<jats:p>Esophageal diseases are common among the population, particularly gastroesophageal reflux disease (GERD). Long-term GERD, delayed diagnosis, and inadequate treatment increase the risk of Barrett's esophagus and esophageal adenocarcinoma. Non-reflux-related esophageal diseases, such as infectious and eosinophilic esophagitis, are becoming increasingly common. Damage to the esophageal mucosa is caused by an imbalance between protective and aggressive factors. The main groups of drugs used to treat GERD include proton pump inhibitors (PPIs), potassium-competitive proton pump inhibitors, alginates, antacids, and prokinetic agents. Recently, a group of esophageal protectors based on hyaluronic acid and alginates has been actively used. We conducted a study to evaluate the effectiveness of combination therapy for reflux esophagitis B-D associated with GERD, including a proton pump inhibitor (PPI) and the domestically produced esophageal protector Ezogard. Adding the esophageal protector Ezogard to the combination GERD treatment (lifestyle and PPI) for one month results in faster relief of the main symptom – heartburn – and more effective healing of esophageal mucosal erosions.</jats:p>